Evaluating the efficacy and safety of SHR-1701 combined with chemotherapy for the perioperative treatment of locally advanced resectable Siewert type II adenocarcinoma of the esophagogastric junction.
HB≥90g/L；
ANC≥1.5×109/L；
PLT≥100×109/L；
ALT and AST<2.5ULN（liver metastasis: ALT and AST<5ULN）；
Known signs of active bleeding from the lesion (except for a positive fecal occult blood test);
Diagnosis of HER2-positive adenocarcinoma of the stomach or gastroesophageal junction;
Cardia or pyloric obstruction;
Currently participating in an interventional clinical trial, or having received treatment with another investigational drug or device within 4 weeks prior to the first dose;
Single group
SHR-1701+SOX
DrugSHR-1701: 1800mg, iv, d1, q3w； SOX: S-1：40 mg (BSA\<1.25 m2) , 50 mg (BSA1.25-1.5 m2) , or 60 mg (BSA≥ 1.5 m2) , po bid d1-14; Oxaliplatin：130 mg/m2 IV D1；
pathological Complete Response(pCR)
No residual invasive cancer cells were found under microscopic examination of the resected tumor tissue and regional lymph node samples.
R0 resection rate
The tumor was completely removed during surgery, and microscopic examination of the resected tissue margins revealed no residual cancer cells.
Major Pathological Response(MPR)
Following neoadjuvant therapy, the proportion of viable tumor cells observed under a microscope in the surgically resected specimen is ≤10%.
PFS(Progression-Free Survival)
The time from the start of treatment until tumor progression or death from any cause.
OS(Overall Survival )
Time from enrollment to death from any cause. For subjects who were still alive at the time of the last follow-up, their overall survival was censored on the date of the last follow-up.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
